Equities research analysts forecast that NxStage Medical, Inc. (NASDAQ:NXTM) will announce sales of $104.45 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for NxStage Medical’s earnings. The lowest sales estimate is $104.30 million and the highest is $104.59 million. NxStage Medical posted sales of $93.01 million during the same quarter last year, which suggests a positive year over year growth rate of 12.3%. The firm is expected to announce its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that NxStage Medical will report full-year sales of $104.45 million for the current financial year, with estimates ranging from $394.93 million to $398.30 million. For the next financial year, analysts expect that the business will post sales of $436.18 million per share, with estimates ranging from $435.90 million to $436.45 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow NxStage Medical.
NXTM has been the topic of a number of recent research reports. Northland Securities reiterated a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research note on Wednesday, November 8th. Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. ValuEngine lowered NxStage Medical from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. BidaskClub raised NxStage Medical from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Finally, Canaccord Genuity reissued a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating and nine have given a hold rating to the company. NxStage Medical presently has an average rating of “Hold” and an average target price of $30.25.
In other news, SVP Winifred L. Swan sold 3,500 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $25.73, for a total transaction of $90,055.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 10,500 shares of company stock worth $265,860 over the last three months. Corporate insiders own 4.70% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Public Employees Retirement Association of Colorado acquired a new position in NxStage Medical during the fourth quarter worth about $128,000. Prudential Financial Inc. acquired a new position in NxStage Medical during the third quarter worth about $202,000. Amalgamated Bank grew its holdings in NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after acquiring an additional 553 shares during the period. Athos Capital Ltd acquired a new position in NxStage Medical during the third quarter worth about $557,000. Finally, Suntrust Banks Inc. grew its holdings in NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after acquiring an additional 209 shares during the period. 84.37% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/13/104-45-million-in-sales-expected-for-nxstage-medical-inc-nxtm-this-quarter.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.